Video

Role of Adjuvant Radiation Therapy in Melanoma

For High-Definition, Click

Adjuvant radiation therapy reduces the risk of local recurrence in patients with high-risk melanoma, notes Robert H. I. Andtbacka, MD, CM. However, this benefit does not translate into an extension in overall survival or control of distant recurrences. Additionally, Andtbacka notes, radiation therapy is accompanied by increased locoregional symptoms, with areas of the head and neck being less impacted compared with the groin.

If wound healing is sluggish as a result of obesity or other condition, radiation should not be considered, suggests Jeffrey A. Sosman, MD. Additionally, as a result of the added toxicity, treatment selection should focus on the patient’s health and the presences of extracapsular extension. However, even when extracapsular extensions are present, Andtbacka advises against radiation to groin areas.

In the ECOG-1609 trial, adjuvant ipilimumab is being compared with high-dose interferon alfa-2b in patients with high-risk stage III-IV melanoma. In this trial, enrollment does not exclude previous adjuvant radiation therapy, notes Omid Hamid, MD. As a result, findings from this study will provide further information on long-term outcomes with radiation therapy.

Related Videos
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.